Jan Westerink
Overview
Explore the profile of Jan Westerink including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
128
Citations
1258
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Helmink M, Peters S, Westerink J, Harris K, Tillmann T, Woodward M, et al.
Eur J Prev Cardiol
. 2024 Apr;
31(14):1671-1678.
PMID: 38584392
Aims: Identifying patients with established cardiovascular disease (CVD) who are at high risk of type 2 diabetes (T2D) may allow for early interventions, reducing the development of T2D and associated...
2.
Helmink M, Hageman S, Eliasson B, Sattar N, Visseren F, Dorresteijn J, et al.
Diabetes Obes Metab
. 2024 Mar;
26(6):2229-2238.
PMID: 38456579
Aims: To develop and externally validate the LIFE-T1D model for the estimation of lifetime and 10-year risk of cardiovascular disease (CVD) in individuals with type 1 diabetes. Materials And Methods:...
3.
Been R, Noordstar E, Helmink M, van Sloten T, de Ranitz-Greven W, van Beek A, et al.
Diagnosis (Berl)
. 2024 Feb;
11(3):312-320.
PMID: 38414181
Objectives: Type 2 diabetes (T2DM) is associated with increased risk for cardiovascular disease (CVD). Whether screen-detected T2DM, based on fasting plasma glucose (FPG) or on HbA, are associated with different...
4.
Castelijns M, Hageman S, Teraa M, van der Meer M, Westerink J, Berg J, et al.
Heart
. 2024 Jan;
110(7):482-490.
PMID: 38182277
Objective: Assessment of generalisability of guideline-informing trials on antithrombotic treatment intensification to real-world patients with cardiovascular disease (CVD). Methods: Inclusion and exclusion criteria of the Cardiovascular Outcomes for People Using...
5.
de Jong C, van den Hout W, van Dijk C, Heim N, van Dam L, Dronkers C, et al.
Thromb Haemost
. 2023 Nov;
124(6):557-567.
PMID: 37984402
Background: The diagnosis of recurrent ipsilateral deep vein thrombosis (DVT) with compression ultrasonography (CUS) may be hindered by residual intravascular obstruction after previous DVT. A reference CUS, an additional ultrasound...
6.
Helmink M, Westerink J, Hageman S, Koopman M, van der Meer M, Teraa M, et al.
Obes Res Clin Pract
. 2023 Sep;
17(5):383-389.
PMID: 37777400
Objective: To determine the role of waist circumference and metabolic dysfunction in the risk of cancer in individuals with type 2 diabetes (T2D) and to compare this to individuals without...
7.
Schropp L, Westerink J, Nijkeuter M, van Hattum E, Petri B, de Borst G
J Vasc Surg
. 2023 Aug;
78(3):841-842.
PMID: 37599038
No abstract available.
8.
Helmink M, Hageman S, Visseren F, de Ranitz-Greven W, de Valk H, van Sloten T, et al.
Diabet Med
. 2023 Jul;
40(11):e15183.
PMID: 37470718
Aim: To evaluate presence of treatment effect heterogeneity of intensive insulin therapy (INT) on occurrence of major adverse cardiovascular events (MACE) in individuals with type 1 diabetes. Methods: In participants...
9.
Schropp L, Cats R, de Kleijn R, van Hattum E, Middeldorp S, Nijkeuter M, et al.
Res Pract Thromb Haemost
. 2023 Mar;
7(1):100051.
PMID: 36873563
Background: In upper extremity thrombosis research, the occurrence of upper extremity postthrombotic syndrome (UE-PTS) is commonly used as the main outcome parameter. However, there is currently no reporting standard or...
10.
Castelijns M, Hageman S, Teraa M, van der Meer M, Westerink J, Costa F, et al.
Am Heart J
. 2023 Feb;
260:72-81.
PMID: 36841319
Objective: The long-term predictive performance of existing bleeding risk models in patients with various manifestations of cardiovascular disease (CVD) is not well known. This study aims to assess and compare...